Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Executive Officer | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 461,425 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 1,905 · Balance 461,425 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2021 Filed Mar 8, 2021 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 567 | $137.55 | $77,993.12 |
DisclosureSEC source: 0001645113-21-000038 · wf-form4_161523866603519.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,810 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:55 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 16,003 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000033 · wf-form4_161489851500921.xml · derivative · entry 3 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,003 Underlying: Ordinary Shares · 16,003 shares Expires 2031-03-01 F3 · derivative.exercise_date: Options to buy 16,003 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:55 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 8,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000033 · wf-form4_161489851500921.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,377 F2 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:55 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 430 | $152.05 | $65,382.79 |
DisclosureSEC source: 0001645113-21-000033 · wf-form4_161489851500921.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,668 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Share Units vested on February 27, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 1,465 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000021 · wf-form4_161471955562420.xml · derivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,465 | $149.10 | $218,431.50 |
DisclosureSEC source: 0001645113-21-000021 · wf-form4_161471955562420.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 20:38 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 11,336 | $0.00 Strike: $84.68 | $0.00 |
DisclosureSEC source: 0001645113-20-000130 · wf-form4_159925192044380.xml · derivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,336 Underlying: Ordinary Shares · 11,336 shares Expires 2030-08-31 F2 · derivative.exercise_date: Options to buy 11,336 ordinary shares will vest and become exercisable in equal installments on each of September 1, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 20:38 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 5,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000130 · wf-form4_159925192044380.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,633 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on September 1, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.